monoclonal antibody XTL001

a combination of two human high-affinity monoclonal antibodies with affinity to different regions of the HBV surface antigen (HBsAg), for passive immunotherapy for HBV infection; Phase II clinical trials 1/03; RN in first source

Also Known As:

HBV-Ab(XTL)17; HBV-Ab(XTL)19; XTL-001; XTL001 monoclonal antibody

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        monoclonal antibody XTL001: 1
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        monoclonal antibody XTL001: 1
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        monoclonal antibody XTL001: 1

Experts

1.	Witherell, Gary: 1 article (05/2002)

Related Diseases

Infections

05/01/2002 - "XTL-001 showed viral neutralization activity in the Trimera model for HBV infection and was several thousand-fold more active than current antibody-based therapies. "
05/01/2002 - "XTL-001, a combination of two human high-affinity monoclonal antibodies with affinity to different regions of the HBV surface antigen (HBsAg), is under development by XTL Biopharmaceuticals as a potential passive immunotherapy for HBV infection. "

Related Drugs and Biologics

1.	Hepatitis B Surface Antigens (HBsAg)
2.	Surface Antigens (Surface Antigen)
3.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Therapeutics